Abstract:
Sciatica is a common back pain caused by irritation of the sciatic nerve. Current pharmacologic therapies have proven inadequate for many patients with sciatic pain. On the other hand, there is a globally increasing demand for the use and administration of natural medicaments for this disorder. Traditional Persian Medicine (TPM) is a school of medicine and a medicinal plant-based resource for clinical studies put forward by Persian scholars. The aim of the present study is to gather and study the effectiveness of all medicinal plants from five main Persian pharmacopeias. Furthermore, different databases such as PubMed and Scopus have been checked to derive relevant activities for these plants. In all, 99 medicinal plants related to 42 families have been authenticated. Asteraceae and Apiaceae were the most frequent families and roots and seeds were the most reported botanical parts. The employed routes of administration were oral (54%), topical (33%) and rectal (13%). Anti-inflammatory, analgesic activity and antinociceptive properties of medicines are known as some main mechanisms to manage sciatic pain. These functions are possessed by 30%, 15%, and 15% of the studied plants, respectively. Medicaments that can be introduced as lead agents for further investigation are Zingiber officinale Roscoe, Olea europaea L., Strychnos nux-vomica L and Artemisia vulgaris L which showed all of these properties in previous studies. Hence, conducting adducible clinical trials using these lead agents may lead to novel drugs with lesser undesirable and much more therapeutic effects on controlling sciatic pain.
摘要:
坐骨神经痛是由坐骨神经刺激引起的常见背痛。目前的药物疗法已被证明对许多坐骨神经疼痛患者是不够的。另一方面,对于这种疾病的天然药物的使用和给药存在全球增长的需求。传统波斯医学(TPM)是波斯学者提出的一所医学院和基于药用植物的临床研究资源。本研究的目的是从五个主要的波斯药典中收集和研究所有药用植物的有效性。此外,已检查了PubMed和Scopus等不同的数据库,以获取这些植物的相关活动。总之,与42个科有关的99种药用植物已通过认证。菊科和菊科是最常见的科,根和种子是报道最多的植物部分。采用的给药途径为口服(54%),局部(33%)和直肠(13%)。抗炎,药物的镇痛活性和抗伤害感受特性被认为是治疗坐骨神经疼痛的一些主要机制。这些功能由30%拥有,15%,15%的被研究植物,分别。可作为先导剂用于进一步研究的药物是ZingiberofficinaleRoscoe,OleaeuropaeaL.,Strychnosnux-vomicaL和普通蒿L在先前的研究中显示出所有这些特性。因此,使用这些先导剂进行可诱导的临床试验可能会导致新型药物在控制坐骨神经疼痛方面具有较少的不良效果和更多的治疗效果。